Cargando…

Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study

BACKGROUND: Treatment with small molecule tyrosine kinase inhibitors (TKIs) has improved survival in many cancers, yet has been associated with an increased risk of adverse events. Warnings of cardiovascular events are common in drug labels of many TKIs. Despite these warnings, cardiovascular toxici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srikanthan, Amirrtha, Ethier, Josee-Lyne, Ocana, Alberto, Seruga, Bostjan, Krzyzanowska, Monika K., Amir, Eitan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376902/ https://www.ncbi.nlm.nih.gov/pubmed/25815472 http://dx.doi.org/10.1371/journal.pone.0122735

Ejemplares similares

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
por: Ocana, Alberto, et al.
Publicado: (2015)

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression
por: Templeton, Arnoud J., et al.
Publicado: (2016)

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020)

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
por: Zist, Andrej, et al.
Publicado: (2015)

Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
por: Ribnikar, Domen, et al.
Publicado: (2021)

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
por: Ethier, Josee-Lyne, et al.
Publicado: (2017)

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases
por: Ocaña, Alberto, et al.
Publicado: (2016)

Precision Medicine for Adolescent and Young Adult (AYA) Oncology
por: Srikanthan, Amirrtha
Publicado: (2023)

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
por: Ocana, Alberto, et al.
Publicado: (2014)

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
por: Tibau, Ariadna, et al.
Publicado: (2018)

Adolescent and young adult (AYA) oncology: A credentialed area of focused competence in Canada
por: Srikanthan, Amirrtha, et al.
Publicado: (2022)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis
por: Wang, Ying, et al.
Publicado: (2020)

Setting Priorities for a Provincial Adolescent and Young Adult Oncology Program
por: Surujballi, Julian, et al.
Publicado: (2022)

Reforming Refugee Healthcare in Canada: Exploring the Use of Policy Tools
por: Holtzer, Ethan, et al.
Publicado: (2017)

Perceptions and attitudes of medical oncologists regarding fertility preservation and pregnancy in high‐risk cancer patients: A survey among Canadian medical oncologists
por: Alshamsan, Bader, et al.
Publicado: (2022)

Young Women with Breast Cancer: The Current Role of Precision Oncology
por: Srikanthan, Amirrtha, et al.
Publicado: (2023)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
por: Masbuchin, Ainun Nizar, et al.
Publicado: (2022)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7
por: Liu, Qing, et al.
Publicado: (2023)

Variations in Emergency Service Utilization among Cancer Survivors: Results from the Pan-Canadian Experiences of Cancer Patients in Transition Study Survey
por: Delisle, Megan, et al.
Publicado: (2023)

Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience
por: Srikanthan, Amirrtha, et al.
Publicado: (2019)

Metastasectomy in Leiomyosarcoma: A Systematic Review and Pooled Survival Analysis
por: Delisle, Megan, et al.
Publicado: (2022)

Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity
por: Yu, Brian, et al.
Publicado: (2022)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016)

Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol
por: Moradian, Saeed, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
por: Udupa, Karthik S, et al.
Publicado: (2017)

Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2015)

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
por: Pérez-Lamas, Lucía, et al.
Publicado: (2023)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
por: Sun, Yongkun, et al.
Publicado: (2016)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
por: Huang, Liling, et al.
Publicado: (2020)

Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
por: Bellantoni, Andrew J., et al.
Publicado: (2021)

Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
por: Ribnikar, Domen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vj1ier9ngith4fmh1bukjeopdi